-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The current pharmaceutical industry is undergoing major shoc.
At the same time, adjustments such as spin-offs, integrations, and sales have become the norm for current pharmaceutical compani.
For example, some time ago, Sihuan Pharmaceutical announced that it plans to propose to sell some or all of its generic drugs and other non-core traditional medicine businesses that have not met performance expectations or long-term strategic goals due to the impact of changes in the pharmaceutical industry and polici.
and assets, the disposal will be completed gradually over the next 12-24 mont.
It is understood that Sihuan Pharmaceutical has accumulated a large number of generic drug products and has a considerable growth ra.
The data shows that in 2021, Sihuan Pharmaceutical’s generic drug business segment revenue will reach 598 billion yuan, accounting for 794% of total reven.
Why did Sihuan Pharmaceutical sell its generic drug business in the context of a considerable growth rate? Industry analysts believe that this is mainly related to Sihuan Pharmaceutical's layout of innovative dru.
Since the completion of the wholly-owned acquisition of Xuanzhu Bio in 2012, Sihuan Pharmaceutical has made every effort to research and develop innovative oncology drugs and new diabetes drugs with high technical barrie.
So far, a total of more than 5 billion yuan has been invested, and two mature innovative R&D platforms have been incubated: Xuanzhu Bio and Huisheng B.
At present, the two companies incubated by Sihuan Pharmaceutical have begun to enter the sprint stage one after anoth.
Among them, Xuanzhu Bio has become one of the most comprehensive companies in the domestic breast cancer tra.
The CDK4/6 inhibitor pirociclib has entered the phase III clinical stage, and the proton pump inhibitor (PPI) Anna with independent intellectual property rights Prazol sodium enteric-coated tablets have also entered the stage of marketing applicati.
The second SGLT-2 inhibitor gaggliflozin produced by Huisheng Biotech has submitted a marketing application; the marketing applications of insulin aspart injection, insulin aspart 30 injection, and insulin aspart 50 injection have been accept.
It is worth mentioning that while accelerating innovation, it has already made some moves in stripping off generic dru.
In 2020, Sihuan Pharmaceutical will dilute the equity of its subsidiary Beijing Ruiye by introducing high-quality new investors to increase capit.
In 2021, the speed of divesting other businesses of Sihuan Pharmaceutical began to accelerate, and the company also sold its shares in Huaiyin Hospital to China Resources Pharmaceutic.
It is becoming a trend in the industry to divest the dwindling business and focus on the core busine.
In recent years, a large number of domestic and foreign pharmaceutical companies have chosen to divest some businesses and focus on the main busine.
Take Sanofi as an examp.
In April this year, Sanofi announced that the French securities market regulator AMF has approved the listing prospectus of its API company EUROA.
Once approved by the general meeting of shareholders, it is expected to be released on MayListed in a spin-off on Euronext Par.
In June, Sanofi sold its longtime partner Regeneron's exclusive worldwide rights to the cancer drug Libtayo for $900 milli.
Recently, it has reached an agreement with Neuraxpharm, and the company will sell 17 drugs to Neuraxpharm for an undisclosed amou.
The drugs are understood to include two product portfolios for central nervous system (CNS) disorders, pain and vascular disorde.
In addition, Novartis also plans to spin off generic drug company Sandoz by the end of this ye.
In fact, talk of Novartis intending to spin off its generics business unit Sandoz has been circulating in the industry since 2019
Recently, Sandoz said that Novartis will make a decision by the end of 2022, either spin off or se.
It is reported that Sandoz was established in 2003 as Novartis' generic drug business unit, and its net sales in 2021 will be 631 billion US dolla.
In general, in recent years, under the background of obvious pressure on profits of pharmaceutical companies, approaching the patent cliff, and generally facing challenges in cost control and many other aspects, in order to have a better development status, a large number of domestic and foreign pharmaceutical companies are choosing to actively focus Main business, speed up "slimmin.
From this, it can be foreseen that in the future, only by optimizing resource allocation and focusing more on core business, can we win more development opportunities in the fierce market competiti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
At the same time, adjustments such as spin-offs, integrations, and sales have become the norm for current pharmaceutical compani.
For example, some time ago, Sihuan Pharmaceutical announced that it plans to propose to sell some or all of its generic drugs and other non-core traditional medicine businesses that have not met performance expectations or long-term strategic goals due to the impact of changes in the pharmaceutical industry and polici.
and assets, the disposal will be completed gradually over the next 12-24 mont.
It is understood that Sihuan Pharmaceutical has accumulated a large number of generic drug products and has a considerable growth ra.
The data shows that in 2021, Sihuan Pharmaceutical’s generic drug business segment revenue will reach 598 billion yuan, accounting for 794% of total reven.
Why did Sihuan Pharmaceutical sell its generic drug business in the context of a considerable growth rate? Industry analysts believe that this is mainly related to Sihuan Pharmaceutical's layout of innovative dru.
Since the completion of the wholly-owned acquisition of Xuanzhu Bio in 2012, Sihuan Pharmaceutical has made every effort to research and develop innovative oncology drugs and new diabetes drugs with high technical barrie.
So far, a total of more than 5 billion yuan has been invested, and two mature innovative R&D platforms have been incubated: Xuanzhu Bio and Huisheng B.
At present, the two companies incubated by Sihuan Pharmaceutical have begun to enter the sprint stage one after anoth.
Among them, Xuanzhu Bio has become one of the most comprehensive companies in the domestic breast cancer tra.
The CDK4/6 inhibitor pirociclib has entered the phase III clinical stage, and the proton pump inhibitor (PPI) Anna with independent intellectual property rights Prazol sodium enteric-coated tablets have also entered the stage of marketing applicati.
The second SGLT-2 inhibitor gaggliflozin produced by Huisheng Biotech has submitted a marketing application; the marketing applications of insulin aspart injection, insulin aspart 30 injection, and insulin aspart 50 injection have been accept.
It is worth mentioning that while accelerating innovation, it has already made some moves in stripping off generic dru.
In 2020, Sihuan Pharmaceutical will dilute the equity of its subsidiary Beijing Ruiye by introducing high-quality new investors to increase capit.
In 2021, the speed of divesting other businesses of Sihuan Pharmaceutical began to accelerate, and the company also sold its shares in Huaiyin Hospital to China Resources Pharmaceutic.
It is becoming a trend in the industry to divest the dwindling business and focus on the core busine.
In recent years, a large number of domestic and foreign pharmaceutical companies have chosen to divest some businesses and focus on the main busine.
Take Sanofi as an examp.
In April this year, Sanofi announced that the French securities market regulator AMF has approved the listing prospectus of its API company EUROA.
Once approved by the general meeting of shareholders, it is expected to be released on MayListed in a spin-off on Euronext Par.
In June, Sanofi sold its longtime partner Regeneron's exclusive worldwide rights to the cancer drug Libtayo for $900 milli.
Recently, it has reached an agreement with Neuraxpharm, and the company will sell 17 drugs to Neuraxpharm for an undisclosed amou.
The drugs are understood to include two product portfolios for central nervous system (CNS) disorders, pain and vascular disorde.
In addition, Novartis also plans to spin off generic drug company Sandoz by the end of this ye.
In fact, talk of Novartis intending to spin off its generics business unit Sandoz has been circulating in the industry since 2019
Recently, Sandoz said that Novartis will make a decision by the end of 2022, either spin off or se.
It is reported that Sandoz was established in 2003 as Novartis' generic drug business unit, and its net sales in 2021 will be 631 billion US dolla.
In general, in recent years, under the background of obvious pressure on profits of pharmaceutical companies, approaching the patent cliff, and generally facing challenges in cost control and many other aspects, in order to have a better development status, a large number of domestic and foreign pharmaceutical companies are choosing to actively focus Main business, speed up "slimmin.
From this, it can be foreseen that in the future, only by optimizing resource allocation and focusing more on core business, can we win more development opportunities in the fierce market competiti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
